Having trouble accessing articles? Reset your cache.

Clazosentan: Phase III data

Top-line data from the double-blind, international Phase III CONSCIOUS-2 trial in >1,150 patients showed that 5 mg/h IV clazosentan missed the primary endpoint of significantly reducing cerebral vasospasm-related morbidity and

Read the full 302 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE